A 65-year-old woman attends for her NHS breast screening mammogram. She mentions that her sister was diagnosed with ovarian cancer at age 58, and her maternal aunt had breast cancer at age 52. She asks whether she should have genetic testing. Which criterion from the NICE guidelines would indicate referral to genetic services for possible BRCA testing?
Q32
A 47-year-old man attends for advice about physical activity. He has a BMI of 29 kg/m², hypertension controlled on ramipril, and works a sedentary office job. He currently does no regular exercise. According to UK Chief Medical Officers' physical activity guidelines, what is the minimum recommended amount of moderate-intensity aerobic activity per week for adults?
Q33
A 51-year-old woman attends for discussion about her NHS breast screening invitation. She has read online about overdiagnosis and wants to understand what this means. Which statement best explains the concept of overdiagnosis in breast cancer screening?
Q34
A 56-year-old woman with type 2 diabetes attends for her annual diabetic eye screening. The report shows dot and blot haemorrhages in all four quadrants, venous beading in two quadrants, and intraretinal microvascular abnormalities (IRMA) in one quadrant. No neovascularisation is seen. What grade of diabetic retinopathy does this represent?
Q35
A 54-year-old man attends for his first NHS Health Check. He asks about the cholesterol blood test. What is the primary lipid measurement used to assess cardiovascular risk in the NHS Health Check programme?
Q36
A 63-year-old man attends for results of his NHS bowel cancer screening FIT test showing 120 micrograms Hb/g faeces. He underwent colonoscopy which identified a 3cm polyp in the sigmoid colon. Histology confirms a tubulovillous adenoma with high-grade dysplasia, completely excised with clear margins. He asks about his ongoing screening. What is the most appropriate surveillance strategy for this patient?
Q37
A 43-year-old woman with a family history of breast cancer asks about risk-reducing strategies. Her mother was diagnosed with breast cancer at age 48 and her maternal aunt at age 52. She has no personal history of breast disease. She does not meet criteria for genetic testing. Which lifestyle modification is supported by the strongest evidence for breast cancer risk reduction in this patient?
Q38
A 71-year-old woman with type 2 diabetes, hypertension, and stage 3a CKD attends for cardiovascular risk assessment. Her medications include metformin, ramipril, and amlodipine. She has never smoked. Her BP is 134/78 mmHg, BMI 29 kg/m², total cholesterol 5.2 mmol/L, LDL 3.1 mmol/L, HDL 1.3 mmol/L. She is not currently on a statin. According to NICE guidelines, what is the most appropriate approach to lipid management?
Q39
A 55-year-old man with type 2 diabetes for 6 years attends for his annual diabetic retinopathy screening result. The report indicates R1 (background retinopathy) with microaneurysms in both eyes. His HbA1c is 64 mmol/mol, BP 142/86 mmHg. He asks what this result means and what follow-up is needed. What is the most appropriate screening interval for diabetic retinopathy in this patient?
Q40
A 32-year-old woman attends with her cervical screening result showing hrHPV negative. She mentions that 2 years ago, at her previous screen, the result was hrHPV positive with normal cytology and she was recalled at 12 months, at which time hrHPV was still positive with normal cytology. She asks why she has been told to attend again in 3 years rather than sooner given her previous positive results. What is the most appropriate explanation?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 31: A 65-year-old woman attends for her NHS breast screening mammogram. She mentions that her sister was diagnosed with ovarian cancer at age 58, and her maternal aunt had breast cancer at age 52. She asks whether she should have genetic testing. Which criterion from the NICE guidelines would indicate referral to genetic services for possible BRCA testing?
A. One first-degree relative with breast cancer under 60 years
B. Two relatives on the same side of the family with ovarian cancer at any age (Correct Answer)
C. One second-degree relative with breast cancer under 50 years
D. One first-degree relative with ovarian cancer over 50 years
E. Three relatives on different sides of the family with breast cancer
Explanation: ***Two relatives on the same side of the family with ovarian cancer at any age***- According to **NICE guidelines (NG164)**, having two or more relatives on the **same side of the family** diagnosed with **ovarian cancer** at any age is a specific criterion for specialist genetic referral.- This reflects the high probability of a **BRCA1** or **BRCA2** mutation within the family, as ovarian cancer is a potent indicator of hereditary breast and ovarian cancer syndrome.*One first-degree relative with breast cancer under 60 years*- A single first-degree relative with breast cancer typically requires the diagnosis to be under **age 40** (not 60) for referral, or the presence of other associated cancers.- Under the age of 60, NICE usually requires **two first-degree relatives** or one first-degree and one second-degree relative to warrant referral.*One second-degree relative with breast cancer under 50 years*- Family history criteria generally prioritize the **number of relatives** and their degree of relatedness; a lone second-degree relative does not meet the threshold for referral regardless of age.- Clinical concern increases if there are multiple second-degree relatives or if the cancer occurs in a **male relative**.*One first-degree relative with ovarian cancer over 50 years*- While ovarian cancer is a significant risk marker, a **single case** (unless the individual has both breast and ovarian cancer) is insufficient for genetic service referral under standard guidelines.- Referral for a single relative with ovarian cancer is usually only considered if they were diagnosed at a **very young age** in specific population groups or if combined with other family history.*Three relatives on different sides of the family with breast cancer*- To meet NICE criteria for genetic risk, the affected relatives must be on the **same side of the family** (either maternal or paternal) to track a single inherited mutation.- Cancer cases on **different sides of the family** are usually treated as separate, lower-risk clusters unless they are individual high-risk cases on both sides.
Question 32: A 47-year-old man attends for advice about physical activity. He has a BMI of 29 kg/m², hypertension controlled on ramipril, and works a sedentary office job. He currently does no regular exercise. According to UK Chief Medical Officers' physical activity guidelines, what is the minimum recommended amount of moderate-intensity aerobic activity per week for adults?
A. 75 minutes per week
B. 100 minutes per week
C. 150 minutes per week (Correct Answer)
D. 200 minutes per week
E. 300 minutes per week
Explanation: ***150 minutes per week***
- The **UK Chief Medical Officers'** guidelines recommend that adults accumulate at least **150 minutes** of **moderate-intensity aerobic activity** per week to maintain health.
- This activity should ideally be spread across the week and can be combined with **muscle-strengthening** activities on at least two days.
*75 minutes per week*
- This is the minimum recommended duration for **vigorous-intensity aerobic activity**, such as running or fast cycling, rather than moderate-intensity.
- Engaging in **vigorous activity** provides similar health benefits in half the time compared to moderate activity.
*100 minutes per week*
- While performing **100 minutes** of activity is better than being sedentary, it falls short of the evidence-based **150-minute threshold** for optimal health outcomes.
- There is no specific UK guideline designating 100 minutes as a primary target for **aerobic exercise**.
*200 minutes per week*
- While exceeding the minimum 150 minutes provides **additional health benefits**, it is not the standard "minimum" recommendation for adults.
- Clinicians should encourage increasing activity levels beyond 150 minutes for further **cardiovascular risk reduction**.
*300 minutes per week*
- This level is often cited for more significant **weight loss** or specific metabolic improvements but is not the baseline public health requirement.
- For a sedentary patient starting out, aiming for **300 minutes** initially may be unrealistic compared to the standard 150-minute goal.
Question 33: A 51-year-old woman attends for discussion about her NHS breast screening invitation. She has read online about overdiagnosis and wants to understand what this means. Which statement best explains the concept of overdiagnosis in breast cancer screening?
A. Detection of breast cancers that are too advanced to treat effectively
B. False positive results leading to unnecessary biopsies
C. Detection of cancers that would never have caused symptoms or death in the woman's lifetime (Correct Answer)
D. Missing breast cancers due to limitations of mammography
E. Detecting breast cancers in women outside the screening age range
Explanation: ***Detection of cancers that would never have caused symptoms or death in the woman's lifetime***
- **Overdiagnosis** refers specifically to the identification of true histological malignancies through screening that are **indolent** and would not have clinically progressed within the patient's natural lifespan.
- It leads to **overtreatment**, where patients undergo surgery, radiotherapy, or chemotherapy for a condition that would never have naturally harmed them.
*Detection of breast cancers that are too advanced to treat effectively*
- This describes a **poor prognosis** or screening failure where the cancer is detected at a late stage rather than too early.
- Overdiagnosis is the opposite; it typically involves detecting **very early-stage** or slow-growing lesions like ductal carcinoma in situ (**DCIS**).
*False positive results leading to unnecessary biopsies*
- A **false positive** occurs when an initial screening test is abnormal, but subsequent diagnostic tests prove that **no cancer** is present.
- In overdiagnosis, the woman **actually has cancer** cells present, but the cancer lacks the biological potential to cause clinical disease.
*Missing breast cancers due to limitations of mammography*
- This refers to **false negatives**, where a malignancy is present but not detected by the screening tool.
- These cases often present as **interval cancers**, which appear in the time period between scheduled screening rounds.
*Detecting breast cancers in women outside the screening age range*
- The **NHS Breast Screening Programme** typically targets women aged 50 to 71; detecting cancers outside this range refers to **opportunistic screening** or diagnostic testing.
- This does not define overdiagnosis, as the concept relates to the **biological behavior** of the tumor rather than the patient's age.
Question 34: A 56-year-old woman with type 2 diabetes attends for her annual diabetic eye screening. The report shows dot and blot haemorrhages in all four quadrants, venous beading in two quadrants, and intraretinal microvascular abnormalities (IRMA) in one quadrant. No neovascularisation is seen. What grade of diabetic retinopathy does this represent?
A. Moderate non-proliferative diabetic retinopathy
B. Severe non-proliferative diabetic retinopathy (Correct Answer)
Question 35: A 54-year-old man attends for his first NHS Health Check. He asks about the cholesterol blood test. What is the primary lipid measurement used to assess cardiovascular risk in the NHS Health Check programme?
A. Total cholesterol
B. Non-HDL cholesterol (Correct Answer)
C. LDL cholesterol
D. HDL cholesterol
E. Triglycerides
Explanation: ***Non-HDL cholesterol***- Per **NICE guidelines** and the **NHS Health Check** protocol, **non-HDL cholesterol** is the preferred lipid parameter for assessing **cardiovascular risk**.- It is calculated as **total cholesterol minus HDL cholesterol** and represents the total amount of **atherogenic lipoproteins** (LDL, VLDL, and IDL) in the blood.*Total cholesterol*- While measured during the check, it is used primarily to calculate the **non-HDL** value and the **total cholesterol:HDL ratio**.- On its own, total cholesterol is less predictive of risk than non-HDL because it includes **"good" HDL cholesterol**.*LDL cholesterol*- LDL cholesterol is a significant risk factor, but its calculation often requires a **fasting sample** to be accurate via the Friedewald formula.- **Non-HDL cholesterol** is favored in primary care because it can be measured accurately in **non-fasting** states, unlike calculated LDL.*HDL cholesterol*- HDL is known as **"good" cholesterol** and is used as a component to determine the overall risk profile rather than a primary target.- A high HDL level is generally **cardioprotective**, but it does not serve as the primary measurement for assessing total lipid-related risk.*Triglycerides*- Triglycerides are highly variable and sensitive to recent food intake, making them unsuitable as a **primary screening** tool in non-fasting checks.- While important for specific cases like **metabolic syndrome**, they are not the primary lipid measurement used in the **QRISK3** calculator for general health checks.
Question 36: A 63-year-old man attends for results of his NHS bowel cancer screening FIT test showing 120 micrograms Hb/g faeces. He underwent colonoscopy which identified a 3cm polyp in the sigmoid colon. Histology confirms a tubulovillous adenoma with high-grade dysplasia, completely excised with clear margins. He asks about his ongoing screening. What is the most appropriate surveillance strategy for this patient?
A. Return to routine NHS bowel cancer screening programme (FIT every 2 years)
B. Colonoscopic surveillance at 3 years
C. Colonoscopic surveillance at 1 year (Correct Answer)
D. Colonoscopic surveillance at 6 months
E. Annual FIT testing for 5 years then return to routine screening
Explanation: ***Colonoscopic surveillance at 1 year***
- According to the **British Society of Gastroenterology (BSG)** guidelines, any adenoma **≥10mm** or with **high-grade dysplasia** (HGD) classifies the patient as high-risk.
- This patient's **3cm tubulovillous adenoma** with HGD requires a follow-up colonoscopy at **one year** to ensure clearance and detect early recurrence.
*Return to routine NHS bowel cancer screening programme (FIT every 2 years)*
- Patients meeting **high-risk criteria** are moved into a dedicated surveillance program rather than continuing with standard **population screening**.
- Returning to routine **FIT testing** alone would risk missing metachronous lesions that require direct visual inspection.
*Colonoscopic surveillance at 3 years*
- While a 3-year interval is appropriate for some lower-risk findings, a **3cm lesion with HGD** is too advanced for this delay.
- A **three-year interval** is typically reserved for follow-up *after* the initial one-year clear surveillance colonoscopy has been performed.
*Colonoscopic surveillance at 6 months*
- A **six-month interval** is generally unnecessary for an adenoma that was **completely excised** with clear margins.
- Such frequent surveillance is more commonly associated with **piecemeal excision** of large sessile lesions to check for site recurrence.
*Annual FIT testing for 5 years then return to routine screening*
- **Annual FIT** is not a substitute for colonoscopic surveillance in patients who have already developed **advanced adenomas**.
- Guidelines mandate **visual assessment** (colonoscopy) because FIT has insufficient sensitivity to reliably detect all precancerous polyps during the surveillance period.
Question 37: A 43-year-old woman with a family history of breast cancer asks about risk-reducing strategies. Her mother was diagnosed with breast cancer at age 48 and her maternal aunt at age 52. She has no personal history of breast disease. She does not meet criteria for genetic testing. Which lifestyle modification is supported by the strongest evidence for breast cancer risk reduction in this patient?
A. Maintaining a healthy weight and avoiding obesity, particularly after menopause (Correct Answer)
B. Avoiding all alcohol consumption
C. Taking aspirin 75mg daily as chemoprevention
D. Vitamin D supplementation 4000 IU daily
E. Increasing dietary phytoestrogen intake through soy products
Explanation: ***Maintaining a healthy weight and avoiding obesity, particularly after menopause***
- Obesity is a major modifiable risk factor because **adipose tissue** is the primary source of **estrogen production** via aromatase in postmenopausal women.
- High **serum estrogen levels** directly increase the risk of hormone-receptor-positive breast cancers, making weight management a cornerstone of prevention.
*Avoiding all alcohol consumption*
- While **alcohol consumption** has a dose-dependent relationship with increased breast cancer risk, the overall impact on risk reduction is generally considered less robust than weight management in the population.
- Guidelines suggest limiting intake to less than one drink per day, but **complete avoidance** is not supported by stronger evidence than maintaining a healthy weight.
*Taking aspirin 75mg daily as chemoprevention*
- **Aspirin** and other NSAIDs have shown potential in reducing colorectal cancer risk, but their role in **breast cancer prevention** is not established in clinical guidelines.
- Daily use for breast cancer risk reduction is not recommended due to insufficient evidence and the risk of **gastrointestinal bleeding**.
*Vitamin D supplementation 4000 IU daily*
- Although observational studies suggested a link between **Vitamin D** and cancer, large randomized trials have failed to show a significant reduction in **breast cancer incidence** with supplementation.
- High-dose supplementation (4000 IU) is not indicated for cancer prevention and carries risks of **hypercalciuria and hypercalcemia**.
*Increasing dietary phytoestrogen intake through soy products*
- Evidence regarding **phytoestrogens** (like isoflavones) and breast cancer risk is inconsistent and varies significantly between Western and Asian populations.
- Current guidelines do not recommend increasing soy intake specifically for **breast cancer chemoprevention** due to the lack of clear, reproducible evidence.
Question 38: A 71-year-old woman with type 2 diabetes, hypertension, and stage 3a CKD attends for cardiovascular risk assessment. Her medications include metformin, ramipril, and amlodipine. She has never smoked. Her BP is 134/78 mmHg, BMI 29 kg/m², total cholesterol 5.2 mmol/L, LDL 3.1 mmol/L, HDL 1.3 mmol/L. She is not currently on a statin. According to NICE guidelines, what is the most appropriate approach to lipid management?
A. No statin required as her cholesterol levels are acceptable for her age
B. Calculate QRISK3 score; offer statin if ≥10%
C. Offer atorvastatin 20mg as she has type 2 diabetes regardless of cholesterol level (Correct Answer)
D. Offer atorvastatin 80mg as she has established cardiovascular disease
E. Arrange specialist lipid clinic referral for consideration of PCSK9 inhibitor therapy
Explanation: ***Offer atorvastatin 20mg as she has type 2 diabetes regardless of cholesterol level***- **NICE guidelines** (CG181) recommend offering **atorvastatin 20mg** for the **primary prevention** of CVD to all patients with **Type 2 Diabetes** who have a 10% or greater 10-year risk or those over age 40.- This patient also has **Stage 3a CKD**, which is an independent indication for initiating **atorvastatin 20mg** for primary prevention of cardiovascular events.*No statin required as her cholesterol levels are acceptable for her age*- Statin therapy in Type 2 Diabetes is based on **cardiovascular risk profile**, not on reaching a specific "acceptable" baseline cholesterol level.- Her age and comorbidities places her in a high-risk category where **primary prevention** is clinically indicated regardless of current lipid values.*Calculate QRISK3 score; offer statin if ≥10%*- **QRISK3** is not typically required for patients with Type 2 Diabetes to justify a statin, as most meet the threshold for therapy based on **age** or **organ damage** (like CKD).- In clinical practice, adults with Type 2 Diabetes are considered high risk and should be offered a statin if they are **older than 40** or have complications.*Offer atorvastatin 80mg as she has established cardiovascular disease*- High-intensity **atorvastatin 80mg** is reserved for **secondary prevention** in patients with established CVD (e.g., previous MI, stroke, or PAD).- There is no evidence in the presentation that she has **established cardiovascular disease** yet, making 20mg the appropriate starting dose for primary prevention.*Arrange specialist lipid clinic referral for consideration of PCSK9 inhibitor therapy*- **PCSK9 inhibitors** are specialized treatments reserved for patients with **familial hypercholesterolaemia** or those who fail to reach targets on maximum-dose statins and ezetimibe.- This patient has not yet started first-line therapy with a **low-dose statin**, making a specialist referral for advanced biologics inappropriate at this stage.
Question 39: A 55-year-old man with type 2 diabetes for 6 years attends for his annual diabetic retinopathy screening result. The report indicates R1 (background retinopathy) with microaneurysms in both eyes. His HbA1c is 64 mmol/mol, BP 142/86 mmHg. He asks what this result means and what follow-up is needed. What is the most appropriate screening interval for diabetic retinopathy in this patient?
A. Urgent ophthalmology referral within 2 weeks
B. Routine ophthalmology referral for assessment within 6 weeks
C. Repeat retinopathy screening in 6 months
D. Repeat retinopathy screening in 12 months (Correct Answer)
E. Discharge from retinopathy screening as stable findings
Explanation: ***Repeat retinopathy screening in 12 months***
- **R1 (background retinopathy)** is characterized by **microaneurysms** and is considered the earliest stage of diabetic retinopathy without immediate sight-threatening features.
- Patients with **R1 changes** and no maculopathy typically follow a **12-month (annual) screening interval**, while emphasizing **HbA1c** and **blood pressure** control to prevent progression.
*Urgent ophthalmology referral within 2 weeks*
- This referral pathway is reserved for **R3 (proliferative retinopathy)**, which involves **neovascularization** or vitreous hemorrhage, indicating a sight-threatening emergency.
- It is also indicated for sudden, severe **visual loss** or rubeosis iridis, which are not described in this patient's R1 report.
*Routine ophthalmology referral for assessment within 6 weeks*
- Routine ophthalmology referral is typically indicated for **R2 (pre-proliferative retinopathy)**, characterized by signs like cotton wool spots, or **M1 (maculopathy)**.
- **Background retinopathy (R1)** without maculopathy is managed within the standard diabetic retinopathy screening program, not via routine ophthalmology referral.
*Repeat retinopathy screening in 6 months*
- **Six-monthly screening** is usually reserved for specific high-risk scenarios, such as stable **pre-proliferative disease** or for patients managed under a digital surveillance clinic.
- For a standard finding of **R1 background retinopathy** without other complications, increasing screening frequency to 6 months is not the standard clinical guideline.
*Discharge from retinopathy screening as stable findings*
- Patients with type 2 diabetes require lifelong screening because they remain at constant risk for **sight-threatening complications** as long as the underlying disease persists.
- **R1 findings** indicate that early retinal damage has begun, necessitating continued monitoring rather than discharge to detect any potential **progression**.
Question 40: A 32-year-old woman attends with her cervical screening result showing hrHPV negative. She mentions that 2 years ago, at her previous screen, the result was hrHPV positive with normal cytology and she was recalled at 12 months, at which time hrHPV was still positive with normal cytology. She asks why she has been told to attend again in 3 years rather than sooner given her previous positive results. What is the most appropriate explanation?
A. The previous hrHPV positive results were false positives and can be disregarded
B. hrHPV clearance has occurred; she returns to routine 3-yearly screening as the current negative result indicates low risk (Correct Answer)
C. She should be recalled in 12 months as previous persistent HPV infection indicates higher risk
D. She needs colposcopy referral as HPV clearance after persistent infection suggests immune suppression
E. She should have annual screening for the next 10 years due to previous HPV persistence
Explanation: ***hrHPV clearance has occurred; she returns to routine 3-yearly screening as the current negative result indicates low risk***- In the NHS cervical screening programme, a woman who becomes **hrHPV negative** after previous persistent infection is considered at **very low risk** for cervical disease.- A negative hrHPV result warrants a return to **routine recall intervals** (every 3 years for those aged 25-49) regardless of previous positive results.*The previous hrHPV positive results were false positives and can be disregarded*- These results were likely **true positives** reflecting a **transient infection** that the immune system has now successfully cleared.- Calling them false positives is medically inaccurate as **HPV clearance** within 1-2 years is a well-documented clinical occurrence.*She should be recalled in 12 months as previous persistent HPV infection indicates higher risk*- A **12-month recall** is only used when the current result is hrHPV positive with **normal cytology** to monitor for persistence.- Since the current test is negative, the short-term risk of developing **CIN3 or cervical cancer** is negligible, making frequent testing unnecessary.*She needs colposcopy referral as HPV clearance after persistent infection suggests immune suppression*- **Colposcopy** is indicated if hrHPV is persistent for 24 months or if there are **cytological abnormalities**, neither of which apply here.- **HPV clearance** is actually a sign of a robust and effective **immune response**, not immune suppression.*She should have annual screening for the next 10 years due to previous HPV persistence*- There is no clinical guideline suggesting **annual screening** for a decade following a single period of HPV persistence that has now resolved.- Excessive screening increases the risk of **over-diagnosis** and unnecessary patient anxiety without providing additional prophylactic benefit.
